A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Veliparib (Primary)
- Indications Brain metastases; Solid tumours
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.